PubMed

National Library of Medicine



About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 9 Review: 3

Items 1 - 9 of 9 On

1: Rijkers DT, Hoppener JW, Posthuma G, Lips CJ, Liskamp RM. Related Article

Inhibition of amyloid fibril formation of human amylin by N-alkylated amin and alpha-hydroxy acid residue containing peptides.
Chemistry. 2002 Sep 16;8(18):4285-91.
PMID: 12298020 [PubMed - indexed for MEDLINE]

2: Poyner DR, Taylor GM, Tomlinson AE, Richardson AG, Smith DM. Related Article

Characterization of receptors for calcitonin gene-related peptide and adrenomedullin on the guinea-pig vas deferens.
Br J Pharmacol. 1999 Mar;126(5):1276-82.
PMID: 10205019 [PubMed - indexed for MEDLINE]

3: Poyner DR, Soomets U, Howitt SG, Langel U. Related Article

Structural determinants for binding to CGRP receptors expressed by human N-MC and Col 29 cells: studies with chimeric and other peptides.
Br J Pharmacol. 1998 Aug;124(8):1659-66.
PMID: 9756381 [PubMed - indexed for MEDLINE]

4: Kiess W, Kapellen T, Siebler T, Dost A, Deutscher J, Nietzschmann U. Related Article

Improvements and new potentials in pharmacological therapy of diabetes me in children and adolescents.
Horm Res. 1998;50 Suppl 1:87-90. Review.
PMID: 9677006 [PubMed - indexed for MEDLINE]

5: Poyner DR. Related Article

Molecular pharmacology of receptors for calcitonin-gene-related peptide, an and adrenomedullin.
Biochem Soc Trans. 1997 Aug;25(3):1032-6. Review. No abstract available.
PMID: 9388596 [PubMed - indexed for MEDLINE]

6: Abe K, Kato M, Saito H. Related Article

Human amylin mimics amyloid beta protein-induced reactive gliosis and inhibition of cellular redox activity in cultured astrocytes.
Brain Res. 1997 Jul 11;762(1-2):285-8.
PMID: 9262192 [PubMed - indexed for MEDLINE]

7: Tomlinson AE, Poyner DR. Related Article

Multiple receptors for calcitonin gene-related peptide and amylin on guinea- ileum and vas deferens.
Br J Pharmacol. 1996 Mar;117(6):1362-8.

PMID: 8882637 [PubMed - indexed for MEDLINE]

8: Lowry F. Related Article

Compound could help diabetic patients walk tightrope between heperglycem hypoglycemia.
CMAJ. 1996 Mar 1;154(5):705-7.
PMID: 8603330 [PubMed - indexed for MEDLINE]

9: Poyner D. Related Article

Pharmacology of receptors for calcitonin gene-related peptide and amylin.
Trends Pharmacol Sci. 1995 Dec;16(12):424-8. Review.
PMID: 8578616 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

Items 1 - 4 of 4 On

1: Nyholm B, Brock B, Orskov L, Schmitz O. Related Article

Amylin receptor agonists: a novel pharmacological approach in the manager of insulin-treated diabetes mellitus.
Expert Opin Investig Drugs. 2001 Sep;10(9):1641-52. Review.
PMID: 11772274 [PubMed - indexed for MEDLINE]

2: Ahren B, Gutniak M. Related Article

No correlation between insulin and islet amyloid polypeptide after stimulatic with glucagon-like peptide-1 in type 2 diabetes.
Eur J Endocrinol. 1997 Dec;137(6):643-9.
PMID: 9437230 [PubMed - indexed for MEDLINE]

3: Whitehouse FW. Related Article

Insulin therapy and its shortcomings - the need for new approaches.
Diabet Med. 1997 Jun;14 Suppl 2:S5-8. Review.
PMID: 9212322 [PubMed - indexed for MEDLINE]

4: Raynaud A, Cohen R, Modigliani E. Related Article

[Calcitonin gene-related peptide (CGRP)]
Presse Med. 1994 Feb 5;23(4):171-5. Review. French.
PMID: 8177860 [PubMed - indexed for MEDLINE]

Did you mean: *protease **resistant** prion protein and amyloid* (95 items)

Display Summary Show: 20 Sort Send to Text

All: 25 Review: 1

Items 1 - 20 of 25 Page 1 of 2

1: Tayebi M, Enever P, Sattar Z, Collinge J, Hawke S. Related Article

Disease-Associated Prion Protein Elicits Immunoglobulin M Responses In V
Mol Med. 2004 Dec 9; [Epub ahead of print]
PMID: 15706401 [PubMed - as supplied by publisher]

2: Bocharova OV, Breydo L, Parfenov AS, Salnikov VV, Baskakov IV. Related Article

In vitro conversion of full-length mammalian prion protein produces amyloi form with physical properties of PrP(Sc).
J Mol Biol. 2005 Feb 18;346(2):645-59. Epub 2004 Dec 19.
PMID: 15670611 [PubMed - indexed for MEDLINE]

3: Cosentino U, Vari MR, Saracino AA, Pitea D, Moro G, Salmona M. Related Article

Tetracycline and its analogues as inhibitors of amyloid fibrils: searching for geometrical pharmacophore by theoretical investigation of their conformatio behavior in aqueous solution.
J Mol Model (Online). 2005 Feb;11(1):17-25. Epub 2004 Dec 9.
PMID: 15592898 [PubMed - as supplied by publisher]

4: Bousset L, Redeker V, Decottignies P, Dubois S, Le Marechal P, Melki R. Related Article

Structural characterization of the fibrillar form of the yeast Saccharomyces cerevisiae prion Ure2p.
Biochemistry. 2004 May 4;43(17):5022-32.
PMID: 15109261 [PubMed - indexed for MEDLINE]

5: Yin SM, Sy MS, Po T. Related Article

An engineered PrPsc-like molecule from the chimera of mammalian prion p and yeast Ure2p prion-inducing domain.
Acta Biochim Biophys Sin (Shanghai). 2004 Feb;36(2):128-32. Erratum in: Acta Biochim I Sin (Shanghai). 2004 Mar;36(3):176.
PMID: 14970909 [PubMed - indexed for MEDLINE]

6: Vanik DL, Surewicz WK. Related Article

Disease-associated F198S mutation increases the propensity of the recombin prion protein for conformational conversion to scrapie-like form.
J Biol Chem. 2002 Dec 13;277(50):49065-70. Epub 2002 Oct 7.
PMID: 12372829 [PubMed - indexed for MEDLINE]

7: Murphy RM. Related Article

Peptide aggregation in neurodegenerative disease.
Annu Rev Biomed Eng. 2002;4:155-74. Epub 2002 Mar 22. Review.
PMID: 12117755 [PubMed - indexed for MEDLINE]

8: Corsaro A, Thellung S, Russo C, Villa V, Arena S, D'Adamo MC, Paludi D, Rossi Principe D, Damonte G, Benatti U, Aceto A, Tagliavini F, Schettini G, Florio T. Related Article

Expression in E. coli and purification of recombinant fragments of wild type mutant human prion protein.
Neurochem Int. 2002 Jul;41(1):55-63.
PMID: 11918972 [PubMed - indexed for MEDLINE]

9: Bons N, Lehmann S, Nishida N, Mestre-Frances N, Dormont D, Belli P, Delacourte A, Grassi J, Brown P. Related Article

BSE infection of the small short-lived primate Microcebus murinus.
C R Biol. 2002 Jan;325(1):67-74.
PMID: 11862624 [PubMed - indexed for MEDLINE]

10: Gordon DJ, Sciarretta KL, Meredith SC. Related Article

Inhibition of beta-amyloid(40) fibrillogenesis and disassembly of beta-amy (40) fibrils by short beta-amyloid congeners containing N-methyl amino ac alternate residues.
Biochemistry. 2001 Jul 27;40(28):8237-45.
PMID: 11444969 [PubMed - indexed for MEDLINE]

11: Kelker M, Kim C, Chueh PJ, Guimont R, Morre DM, Morre DJ. Related Article

Cancer isoform of a tumor-associated cell surface NADH oxidase (tNOX) l properties of a prion.
Biochemistry. 2001 Jun 26;40(25):7351-4.
PMID: 11412089 [PubMed - indexed for MEDLINE]

12: Supattapone S, Bouzamondo E, Ball HL, Wille H, Nguyen HO, Cohen FE, DeArmond SJ, Prusiner SB, Scott M. Related Article

A protease-resistant 61-residue prion peptide causes neurodegeneration in transgenic mice.
Mol Cell Biol. 2001 Apr;21(7):2608-16.
PMID: 11259607 [PubMed - indexed for MEDLINE]

13: Tagliavini F, Forloni G, Colombo L, Rossi G, Girola L, Canciani B, Angeretti N, Giampaolo L, Peressini E, Awan T, De Gioia L, Ragg E, Bugiani O, Salmona M. Related Article

Tetracycline affects abnormal properties of synthetic PrP peptides and PrP(vitro.
J Mol Biol. 2000 Jul 28;300(5):1309-22.
PMID: 10903871 [PubMed - indexed for MEDLINE]

14: Zanusso G, Petersen RB, Jin T, Jing Y, Kanoush R, Ferrari S, Gambetti P, Singh N. Related Article

Proteasomal degradation and N-terminal protease resistance of the codon 1 mutant prion protein.
J Biol Chem. 1999 Aug 13;274(33):23396-404.
PMID: 10438517 [PubMed - indexed for MEDLINE]

15: Brown P, Cervenakova L, McShane L, Goldfarb LG, Bishop K, Bastian F, Kirkpatrick J, Piccardo P, Ghetti B, Gajdusek DC. Related Article

Creutzfeldt-Jakob disease in a husband and wife.
Neurology. 1998 Mar;50(3):684-8.

PMID: 9521256 [PubMed - indexed for MEDLINE]

16: Holscher C, Delius H, Burkle A. Related Article

Overexpression of nonconvertible PrPc delta114-121 in scrapie-infected m neuroblastoma cells leads to trans-dominant inhibition of wild-type PrP(Sc accumulation.
J Virol. 1998 Feb;72(2):1153-9.
PMID: 9445012 [PubMed - indexed for MEDLINE]

17: Singh N, Zanusso G, Chen SG, Fujioka H, Richardson S, Gambetti P, Petersen RB. Related Article

Prion protein aggregation reverted by low temperature in transfected cells carrying a prion protein gene mutation.
J Biol Chem. 1997 Nov 7;272(45):28461-70.
PMID: 9353306 [PubMed - indexed for MEDLINE]

18: King CY, Tittmann P, Gross H, Gebert R, Aebi M, Wuthrich K. Related Article

Prion-inducing domain 2-114 of yeast Sup35 protein transforms in vitro int amyloid-like filaments.
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6618-22.
PMID: 9192614 [PubMed - indexed for MEDLINE]

19: Piccardo P, Seiler C, Dlouhy SR, Young K, Farlow MR, Prelli F, Frangione B, Bugiani O, Tagliavini F, Ghetti B. Related Article

Proteinase-K-resistant prion protein isoforms in Gerstmann-Straussler-Sch disease (Indiana kindred).
J Neuropathol Exp Neurol. 1996 Nov;55(11):1157-63.
PMID: 8939199 [PubMed - indexed for MEDLINE]

20: Wille H, Zhang GF, Baldwin MA, Cohen FE, Prusiner SB. Related Article

Separation of scrapie prion infectivity from PrP amyloid polymers.
J Mol Biol. 1996 Jun 21;259(4):608-21.
PMID: 8683568 [PubMed - indexed for MEDLINE]

Items 1 - 20 of 25 Page 1 of 2

Display Summary Show: 20 Sort Send to Text

All: 25 Review: 1

Items 21 - 25 of 25 Previous Page 2

21: Wille H, Baldwin MA, Cohen FE, DeArmond SJ, Prusiner SB. Related Article

Prion protein amyloid: separation of scrapie infectivity from PrP polymers.
Ciba Found Symp. 1996;199:181-99; discussion 199-201.
PMID: 8915611 [PubMed - indexed for MEDLINE]

22: Selvaggini C, De Gioia L, Cantu L, Ghibaudi E, Diomede L, Passerini F, Forloni G, Bugiani O, Tagliavini F, Salmona M. Related Article

Molecular characteristics of a protease-resistant, amyloidogenic and neurot peptide homologous to residues 106-126 of the prion protein.
Biochem Biophys Res Commun. 1993 Aug 16;194(3):1380-6.
PMID: 8102526 [PubMed - indexed for MEDLINE]

23: Forloni G, Angeretti N, Chiesa R, Monzani E, Salmona M, Bugiani O, Tagliavini F. Related Article

Neurotoxicity of a prion protein fragment.
Nature. 1993 Apr 8;362(6420):543-6.
PMID: 8464494 [PubMed - indexed for MEDLINE]

24: Nagano K, Miki T, Yoshioka K, Katsumi D, Katsuya T, Takeda M, Ikeda M, Tanabe H, Nishimura T, Sakai Y, et al. Related Article

[Two kindreds with familial Alzheimer's disease--analysis of the APP717 mutation and the mutated genes for the prion protein]
Nippon Ronen Igakkai Zasshi. 1992 Jun;29(6):509-14. Japanese.
PMID: 1356166 [PubMed - indexed for MEDLINE]

25: Safar J, Ceroni M, Gajdusek DC, Gibbs CJ Jr. Related Article

Differences in the membrane interaction of scrapie amyloid precursor prote normal and scrapie- or Creutzfeldt-Jakob disease-infected brains.
J Infect Dis. 1991 Mar;163(3):488-94.
PMID: 1671680 [PubMed - indexed for MEDLINE]

Items 21 - 25 of 25 Previous Page 2

Display Summary Show: 20 Sort Send to Text

About Entrez
Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
My NCBI (Cubby)

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

All: 8 Review: 4

Items 1 - 8 of 8 On

1: Vidal J, Verchere CB, Andrikopoulos S, Wang F, Hull RL, Cnop M, Olin KL, LeBoeuf RC, O'Brien KD, Chait A, Kahn SE. Related Article

The effect of apolipoprotein E deficiency on islet amyloid deposition in hum islet amyloid polypeptide transgenic mice.
Diabetologia. 2003 Jan;46(1):71-9. Epub 2003 Jan 9.
PMID: 12637985 [PubMed - indexed for MEDLINE]

2: Jaikaran ET, Clark A. Related Article

Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology.
Biochim Biophys Acta. 2001 Nov 29;1537(3):179-203. Review.
PMID: 11731221 [PubMed - indexed for MEDLINE]

3: Clark A, Jones LC, de Koning E, Hansen BC, Matthews DR. Related Article

Decreased insulin secretion in type 2 diabetes: a problem of cellular mass or function?
Diabetes. 2001 Feb;50 Suppl 1:S169-71.
PMID: 11272183 [PubMed - indexed for MEDLINE]

4: Kahn SE, Andrikopoulos S, Verchere CB. Related Article

Islet amyloid: a long-recognized but underappreciated pathological feature o 2 diabetes.
Diabetes. 1999 Feb;48(2):241-53. Review.
PMID: 10334297 [PubMed - indexed for MEDLINE]

5: Ahren B, Oosterwijk C, Lips CJ, Hoppener JW. Related Article

Transgenic overexpression of human islet amyloid polypeptide inhibits insul secretion and glucose elimination after gastric glucose gavage in mice.
Diabetologia. 1998 Nov;41(11):1374-80.
PMID: 9833947 [PubMed - indexed for MEDLINE]

6: de Koning EJ, Fleming KA, Gray DW, Clark A. Related Article

High prevalence of pancreatic islet amyloid in patients with end-stage renal on dialysis treatment.
J Pathol. 1995 Feb;175(2):253-8.
PMID: 7738722 [PubMed - indexed for MEDLINE]

7: Tan SY, Pepys MB. Related Article

Amyloidosis.
Histopathology. 1994 Nov;25(5):403-14. Review.
PMID: 7868080 [PubMed - indexed for MEDLINE]

8: Cohen AS, Jones LA.

Related Article

Amyloidosis.
Curr Opin Rheumatol. 1991 Feb;3(1):125-38. Review.
PMID: 2043438 [PubMed - indexed for MEDLINE]

Display Summary Show: 20 Sort Send to Text

WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Monday, March 21, 2005

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC; THES=ASSIGNEE; PLUR=YES; OP=ADJ		
☐	L4	20000504	36
☐	L3	L2 and (amyloid$4 or cytoprotection)	194
☐	L2	(IAPP or islet amyloid polypeptide? or protease resistant prion protein or PrP-sen or PrPC)	714
☐	L1	(IAPP or islet amyloid polypeptide? or protease resistant prion protein or PrP-sen or PrPC) and samyloid$4	0

END OF SEARCH HISTORY

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 36 of 36 returned.

1. Document ID: US 6054114 A

Using default format because multiple data bases are involved.

L4: Entry 1 of 36 File: USPT Apr 25, 2000

US-PAT-NO: 6054114
DOCUMENT-IDENTIFIER: US 6054114 A

TITLE: Organometallic ligands for the localization and quantification of amyloid in vivo and in vitro

DATE-ISSUED: April 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lansbury, Jr.; Peter T.	Brookline	MA		
Han; Hogyu	Seoul			KR
Cho; Cheon-Gyu	Seoul			KR
Zhen; Weiguo	Waltham	MA		
Harper; James D.	Cambridge	MA		
Davison; Alan	West Roxbury	MA		

US-CL-CURRENT: 424/1.11; 424/9.1, 534/10, 534/12, 534/14, 534/883, 556/45

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

2. Document ID: US 6037327 A

L4: Entry 2 of 36 File: USPT Mar 14, 2000

US-PAT-NO: 6037327
DOCUMENT-IDENTIFIER: US 6037327 A

TITLE: Specific saccharide compositions and methods for treating Alzheimer's disease and other amyloidoses

DATE-ISSUED: March 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Castillo; Gerardo	Seattle	WA		
Snow; Alan D.	Lynnwood	WA		

US-CL-CURRENT: 514/23; 424/709, 514/53, 536/122

ABSTRACT:

A pharmaceutical agent for treating an amyloid disease in a patient, wherein the pharmaceutical agent comprises a saccharide containing at least one substituted anionic group, or a pharmaceutically acceptable salt of the saccharide containing at least one substituted anionic group, and in preferred embodiments is a therapeutically effective amount of glucose pentasulfate. The agent is directed to amyloid diseases in general and to Alzheimer's disease in particular. The pharmaceutical agent may advantageously be combined with a pharmaceutically acceptable carrier, diluent or excipient.

4 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

3. Document ID: US 6034211 A

L4: Entry 3 of 36 File: USPT Mar 7, 2000

US-PAT-NO: 6034211
DOCUMENT-IDENTIFIER: US 6034211 A

TITLE: .beta.-sheet nucleating peptidomimetics

DATE-ISSUED: March 7, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kelly; Jeffery W.	College Station	TX	77840	

US-CL-CURRENT: 530/317; 546/101

ABSTRACT:

N-methylated .beta.-sheet nucleating peptidomimetics containing diarylheterocycle .beta.-turn mimics, and methods of making and using them.

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

4. Document ID: US 6010853 A

L4: Entry 4 of 36 File: USPT Jan 4, 2000

US-PAT-NO: 6010853

DOCUMENT-IDENTIFIER: US 6010853 A

TITLE: Siva genes, novel genes involved in CD27-mediated apoptosis

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kanteti; Prasad V. S.	Boston	MA		
Ao; Zhaohui	Devon	PA		
Schlossman; Stuart F.	Newton Centre	MA		

US-CL-CURRENT: 435/6; 435/320.1, 435/325, 435/69.1, 435/91.4, 435/91.5, 536/23.1, 536/23.4, 536/23.5

ABSTRACT:

The invention provides isolated nucleic acids molecules, designated Siva nucleic acid molecules, which encode proteins involved in immune cell apoptosis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing Siva nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a Siva gene has been introduced or disrupted. The invention still further provides isolated Siva proteins, fusion proteins, antigenic peptides and anti-Siva antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.

16 Claims, 2 Drawing figures
Exemplary Claim Number: 1,8
Number of Drawing Sheets: 3

☐ 5. Document ID: US 6010849 A

L4: Entry 5 of 36 File: USPT Jan 4, 2000

US-PAT-NO: 6010849
DOCUMENT-IDENTIFIER: US 6010849 A

TITLE: Sequence-directed DNA binding molecules compositions and methods

DATE-ISSUED: January 4, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 435/6; 435/7.1

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

11 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 47

☐ 6. Document ID: US 5998367 A

L4: Entry 6 of 36 File: USPT Dec 7, 1999

US-PAT-NO: 5998367
DOCUMENT-IDENTIFIER: US 5998367 A

TITLE: Pramlintide pro H-amylin salts and compositions

DATE-ISSUED: December 7, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gaeta; Laura S. L.	La Jolla	CA		
Jones; Howard	Poway	CA		
Albrecht; Elisabeth	San Diego	CA		

US-CL-CURRENT: 514/12; 514/24, 514/866, 530/324

ABSTRACT:

Agonist analogues of amylin and related pharmaceutical compositions, and methods of treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.

5 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

7. Document ID: US 5942227 A

L4: Entry 7 of 36 File: USPT Aug 24, 1999

US-PAT-NO: 5942227
DOCUMENT-IDENTIFIER: US 5942227 A

TITLE: Pharmaceutical compositions containing antibodies to amylin

DATE-ISSUED: August 24, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J.S.	Auckland			NZ
Greene, Jr.; Howard	Rancho Santa Fe	CA		

US-CL-CURRENT: 424/139.1; 424/141.1, 514/3, 530/387.9

ABSTRACT:

Compositions comprising antibodies directed to amylin in a pharmaceutically acceptable carrier for use in blocking the effects of amylin.

2 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

8. Document ID: US 5935927 A

L4: Entry 8 of 36 File: USPT Aug 10, 1999

US-PAT-NO: 5935927
DOCUMENT-IDENTIFIER: US 5935927 A

TITLE: Compositions and methods for stimulating amyloid removal in amyloidogenic diseases using advanced glycosylation endproducts

DATE-ISSUED: August 10, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Vitek; Michael P.	East Norwich	NY		
Cerami; Anthony	Shelter Island	NY		
Bucala; Richard J.	New York	NY		
Ulrich; Peter C.	Old Tappan	NJ		
Vlassara; Helen	Shelter Island	NJ		
Zhang; Xini	Jericho	NJ		

US-CL-CURRENT: 514/12; 514/23, 514/359, 514/438, 514/439, 514/443, 514/569, 514/642, 514/647, 514/79, 514/91, 514/95, 530/300, 530/322, 536/1.11, 548/100, 548/121, 548/122

ABSTRACT:

The present invention relates generally to methods and compositions for treating amyloidogenic diseases such as Alzheimer's disease and the development of type II diabetes, in which deposition of amyloid in organs such as the brain and pancreas interfere with neurological function and insulin release, respectively. The methods and compositions are directed toward increasing the activity of scavenger cells within the body at recognizing and removing amyloid deposits from affected tissues and organs. Scavenger cells may be targeted to amyloid deposits by means of spontaneously-occurring chemical modifications called advanced glycosylation endproducts (AGEs). Compositions are described which increase scavenger cell activity towards AGE-modified amyloid. Amyloid removal may also be enhanced by increasing AGE levels in amyloid deposits within the body by administering AGE-modified amyloid targeting agents, which after becoming situated at sites containing amyloid, subsequently attract scavenger cells to degrade attendant amyloid. These methods and associated compositions result in a decrease in the extent of amyloid deposits in tissues, reducing the attendant pathology.

9 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 8

☐ 9. Document ID: US 5891641 A

L4: Entry 9 of 36 File: USPT Apr 6, 1999

US-PAT-NO: 5891641
DOCUMENT-IDENTIFIER: US 5891641 A
**** See image for Certificate of Correction ****

TITLE: Assay for disease related conformation of a protein

DATE-ISSUED: April 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Prusiner; Stanley B.	San Francisco	CA		
Safar; Jiri G.	Concord	CA		

US-CL-CURRENT: 435/7.1; 435/960, 435/961, 436/501, 436/518, 436/538, 436/542

ABSTRACT:

An assay method is disclosed which makes it possible to determine the presence of a diseased related conformation of a protein (e.g., PrP.sup.Sc) in a sample. A sample is divided into two portions and the first portion is cross-linked to a first solid support and then contacted with a labelled antibody which binds to a non-disease form of the protein with a higher degree of affinity (e.g, 4 to 30 fold higher)

than to the disease form of the protein. The second portion is treated in a manner which causes any disease form of the protein to change conformation to a form with a higher binding affinity for the labelled antibody. The treated second portion is then bound to a second solid support and contacted with labelled antibody. The level of labelled antibody binding to a protein in the first and second portions is determined and the amounts measured in each are compared. The difference between the two measurements is an indication of whether the diseased related conformation of the protein was present in the sample.

20 Claims, 11 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

10. Document ID: US 5869241 A

L4: Entry 10 of 36 File: USPT Feb 9, 1999

US-PAT-NO: 5869241
DOCUMENT-IDENTIFIER: US 5869241 A

TITLE: Method of determining DNA sequence preference of a DNA-binding molecule

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		
Turin; Lisa M.	Redwood City	CA		
Fry; Kirk E.	Palo Alto	CA		

US-CL-CURRENT: 435/6; 435/91.1, 435/91.2

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

11 Claims, 72 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 47

11. Document ID: US 5854204 A

L4: Entry 11 of 36 File: USPT Dec 29, 1998

US-PAT-NO: 5854204
DOCUMENT-IDENTIFIER: US 5854204 A

TITLE: A.beta. peptides that modulate .beta.-amyloid aggregation

DATE-ISSUED: December 29, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Findeis; Mark A.	Cambridge	MA		
Benjamin; Howard	Lexington	MA		
Garnick; Marc B.	Brookline	MA		
Gefter; Malcolm L.	Lincoln	MA		
Hundal; Arvind	Brighton	MA		
Kasman; Laura	Athens	GA		
Musso; Gary	Hopkinton	MA		
Signer; Ethan R.	Cambridge	MA		
Wakefield; James	Brookline	MA		
Reed; Michael	Marietta	GA		
Molineaux; Susan	Brookline	MA		
Kubasek; William	Belmont	MA		
Chin; Joseph	Salem	MA		
Lee; Jung-Ja	Wayland	MA		
Kelley; Michael	Arlington	MA		

US-CL-CURRENT: 514/2; 514/12, 514/14, 530/324, 530/326

ABSTRACT:

Compounds that modulate the aggregation of amyloidogenic proteins or peptides are disclosed. The modulators of the invention can promote amyloid aggregation or, more preferably, can inhibit natural amyloid aggregation. In a preferred embodiment, the compounds modulate the aggregation of natural .beta. amyloid peptides (.beta.-AP). In a preferred embodiment, the .beta. amyloid modulator compounds of the invention are comprised of an A.beta. aggregation core domain and a modifying group coupled thereto such that the compound alters the aggregation or inhibits the neurotoxicity of natural .beta. amyloid peptides when contacted with the peptides. Furthermore, the modulators are capable of altering natural .beta.-AP aggregation when the natural .beta.-APs are in a molar excess amount relative to the modulators. Pharmaceutical compositions comprising the compounds of the invention, and diagnostic and treatment methods for amyloidogenic diseases using the compounds of the invention, are also disclosed.

10 Claims, 10 Drawing figures

Exemplary Claim Number: 5
Number of Drawing Sheets: 7

12. Document ID: US 5834593 A

L4: Entry 12 of 36 File: USPT Nov 10, 1998

US-PAT-NO: 5834593
DOCUMENT-IDENTIFIER: US 5834593 A

TITLE: Soluble form of PrP.sup.SC which is insoluble in native form

DATE-ISSUED: November 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Prusiner; Stanley B.	San Francisco	CA		
Cohen; Fred E.	San Francisco	CA		
Muramoto; Tamaki	San Francisco	CA		

US-CL-CURRENT: 530/350; 435/23, 435/236, 435/6, 435/7.1, 530/356

ABSTRACT:

The invention includes deleting codon segments from DNA expressing a native protein (e.g., PrP.sup.Sc) in order to obtain a shorter, soluble protein which mimics characteristics of an insoluble native (e.g., PrP.sup.Sc) protein. Soluble proteins of the invention are characterized by: (1) having less amino acids than the full length native protein; (2) having a higher degree of solubility than the native protein; (3) retaining the basic biological characteristics of the native protein such as (a) not being subject to enzymatic digestion and (b) causing disease. Soluble proteins of the invention are obtained by providing a DNA sequence which encodes a native protein and systematically removing codons, making copies of the shortened versions of DNA which are then expressed to provide the shortened proteins. The shortened proteins are then tested for solubility. Soluble proteins are then further tested to confirm that they retain the biological characteristics of the native protein. The soluble form can also be created by adding amino acids, binding a hydrophilic moiety to the native protein or combinations of deleting, adding, and binding hydrophilic moieties to the protein.

4 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

13. Document ID: US 5792901 A

L4: Entry 13 of 36 File: USPT Aug 11, 1998

US-PAT-NO: 5792901
DOCUMENT-IDENTIFIER: US 5792901 A
**** See image for Certificate of Correction ****

TITLE: Detecting prions in a sample and prion preparation and transgenic animal used for same

DATE-ISSUED: August 11, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Prusiner; Stanley B.	San Francisco	CA		
Scott; Michael R.	San Francisco	CA		
Telling; Glenn C.	San Francisco	CA		

US-CL-CURRENT: 800/3; 424/9.1, 800/18, 800/9

ABSTRACT:

The invention includes an artificial PrP gene, a transgenic animal containing a PrP gene of another animal or the artificial PrP gene, a hybrid non-human mammal with an ablated endogenous prion protein gene and exogenous prion protein gene, assay methodology which uses the animals to detect pathogenic prions in a sample and standardized prion preparation used in the assay. The genome of a host animal (such as a mouse), is manipulated so that the animal is rendered susceptible to infection with prions which normally would infect only a genetically diverse test animal (such as human, cow or sheep). A PrP gene of the host is preferably manipulated to include a mutation which matches a mutation which causes prion disease in the genetically diverse mammal. Pathogenic prions in a sample can be detected by injecting the sample to be tested into a mammal of the invention which has been genetically manipulated so as to be susceptible to infection from prions in the sample. Mammals which are not inoculated with the sample and others inoculated with a standardized prion preparation of the invention are used as controls in the assay to detect prions in samples which cause diseases. For example, Creutzfeldt Jakob Disease (CJD) is a fatal neurodegenerative disease of humans caused by prions.

12 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 14. Document ID: US 5780288 A

L4: Entry 14 of 36 File: USPT Jul 14, 1998

US-PAT-NO: 5780288
DOCUMENT-IDENTIFIER: US 5780288 A

TITLE: Process to destroy biological activity in protein-containing feed

DATE-ISSUED: July 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rohwer; Gary L.	Parma	ID	83660	

US-CL-CURRENT: 435/238; 424/451, 426/2, 426/231, 426/573, 426/601, 426/635, 426/98, 530/350

ABSTRACT:

A product and process for animal feed ingredients free of biologically active proteins as well as bacteria and viruses. The process comprises the steps of: treating a proteinaceous mixture with alkali to cause the pH of the mixture to be raised to where proteins in the proteinaceous mixture will be solubilized to form a gel; maintaining the proteinaceous mixture at a temperature in a range between about 50.degree. to 55.degree. C.; adding if needed, sufficient lipid material, to the alkali-treated proteinaceous mixture to provide a dispersion with a ratio of lipid to proteinaceous mixture in a range from about 5 to 80, respectively; determining an optimum pH of solubilization expressed as an alkali hydrogen ion difference on a hydrogen ion difference curve, measuring rate of change of hydrogen ion difference per unit of acid equivalent, ceasing addition of alkali when the slope of the titration curve is essentially zero, adding an acid to the lipid material/proteinaceous mixture dispersion to cause the pH of the dispersion to be lowered to an acidic endpoint where the proteins encapsulate the lipid material; the acidic endpoint being defined by: i) determining a pH of encapsulation by titration, expressed as an acidic hydrogen ion difference on a hydrogen ion difference curve, ii) measuring rate of change of hydrogen ion difference per unit of acid equivalent, iii) ceasing addition of acid when the slope of the titration curve is essentially zero.

4 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 15. Document ID: US 5773572 A

L4: Entry 15 of 36 File: USPT Jun 30, 1998

US-PAT-NO: 5773572
DOCUMENT-IDENTIFIER: US 5773572 A
**** See image for Certificate of Correction ****

TITLE: Fragments of prion proteins

DATE-ISSUED: June 30, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fishleigh; Robert Vincent	Cheshire			GB2
Robson; Barry	Cheshire			GB2
Mee; Roger Paul	Manchester			GB2

US-CL-CURRENT: 530/324; 530/323, 530/326, 530/334, 536/23.5

ABSTRACT:

Synthetic polypeptides having at least one antigenic site of a prion protein are disclosed together methods for their use and manufacture and antibodies raised against such polypeptides. Diagnostic kits using the polypeptides and/or antibodies are also disclosed.

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

16. Document ID: US 5750361 A

L4: Entry 16 of 36 File: USPT May 12, 1998

US-PAT-NO: 5750361
DOCUMENT-IDENTIFIER: US 5750361 A
**** See image for Certificate of Correction ****

TITLE: Formation and use of prion protein (PRP) complexes

DATE-ISSUED: May 12, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Prusiner; Stanley B.	San Francisco	CA		
Kaneko; Kivotoshi	San Francisco	CA		
Cohen; Fred E.	San Francisco	CA		

US-CL-CURRENT: 435/23; 435/188, 435/24, 435/325, 435/6, 436/164, 436/181, 436/2, 530/350, 536/23.1

ABSTRACT:

Prion protein (PrP) peptides having at least one .alpha.-helical domain and forming a random coil conformation in aqueous solutions bind cellular PrP (PrP.sup.C) to form a complex having characteristics of the scrapie isoform (PrP.sup.Sc). Methods for screening compounds able to inhibit or decrease the binding of PrP peptides to PrP.sup.C are disclosed, as well as methods for assaying PrP.sup.Sc.

27 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw De

17. Document ID: US 5744131 A

L4: Entry 17 of 36 File: USPT Apr 28, 1998

US-PAT-NO: 5744131
DOCUMENT-IDENTIFIER: US 5744131 A

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: April 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		

US-CL-CURRENT: 424/78.08; 436/501, 514/1

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

3 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 33

☐ 18. Document ID: US 5738990 A

L4: Entry 18 of 36 File: USPT Apr 14, 1998

US-PAT-NO: 5738990
DOCUMENT-IDENTIFIER: US 5738990 A
**** See image for Certificate of Correction ****

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: April 14, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		

US-CL-CURRENT: 435/6; 435/320.1, 435/69.1, 536/24.1

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

5 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 33

☐ 19. Document ID: US 5726014 A

L4: Entry 19 of 36 File: USPT Mar 10, 1998

US-PAT-NO: 5726014
DOCUMENT-IDENTIFIER: US 5726014 A

TITLE: Screening assay for the detection of DNA-binding molecules

DATE-ISSUED: March 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Watertown	MA		
Turin; Lisa M.	Berkeley	CA		

US-CL-CURRENT: 435/6; 435/91.2, 436/501

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening

libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

19 Claims, 72 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 47

☐ 20. Document ID: US 5716780 A

L4: Entry 20 of 36 File: USPT Feb 10, 1998

US-PAT-NO: 5716780
DOCUMENT-IDENTIFIER: US 5716780 A

TITLE: Method of constructing sequence-specific DNA-binding molecules

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Watertown	MA		

US-CL-CURRENT: 435/6; 436/501

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

9 Claims, 48 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 33

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

21. Document ID: US 5716619 A

L4: Entry 21 of 36 File: USPT Feb 10, 1998

US-PAT-NO: 5716619
DOCUMENT-IDENTIFIER: US 5716619 A

TITLE: Treatment of type 2 diabetes mellitus

DATE-ISSUED: February 10, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J.S.	Woodstock			GB2
Greene, Jr.; Howard	Rancho Santa Fe	CA		

US-CL-CURRENT: 424/130.1; 424/131.1, 424/139.1, 424/141.1, 424/145.1, 424/156.1, 514/12, 514/866

ABSTRACT:

Antibody methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics, are disclosed. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include antibodies directed to amylin and amylin agonist active sites. Other antagonists include anti-idiotype antibodies directed to antibodies directed to amylin.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

22. Document ID: US 5693463 A

L4: Entry 22 of 36 File: USPT Dec 2, 1997

US-PAT-NO: 5693463
DOCUMENT-IDENTIFIER: US 5693463 A

TITLE: Method of ordering sequence binding preferences of a DNA-binding molecule

DATE-ISSUED: December 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Edwards; Cynthia A.	Menlo Park	CA		
Fry; Kirk E.	Palo Alto	CA		
Cantor; Charles R.	Boston	MA		
Andrews; Beth M.	Maynard	MA		

US-CL-CURRENT: 435/6; 435/7.23, 536/23.1

ABSTRACT:

The present invention defines an assay useful for screening libraries of synthetic or biological compounds for their ability to bind specific DNA test sequences. The assay is also useful for determining the sequence specificity and relative DNA-binding affinity of DNA-binding molecules for any particular DNA sequence. Also described herein are potential applications of the assay, including: 1) the detection of lead compounds or new drugs via the mass screening of libraries of synthetic or biological compounds (i.e., fermentation broths); 2) the design of sequence-specific DNA-binding drugs comprised of homo- or hetero-meric subunits of molecules for which the sequence specificity was determined using the assay; and 3) the use of molecules for which sequence specificity was determined using the assay as covalently attached moieties to aid in the binding of nucleic acid or other macromolecular polymers to nucleic acid sequences.

3 Claims, 48 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 33

23. Document ID: US 5686411 A

L4: Entry 23 of 36 File: USPT Nov 11, 1997

US-PAT-NO: 5686411
DOCUMENT-IDENTIFIER: US 5686411 A

TITLE: Amylin agonist peptides and uses therefor

DATE-ISSUED: November 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gaeta; Laura S. L.	Foster City	CA		
Jones; Howard	Poway	CA		
Albrecht; Elisabeth	San Diego	CA		

US-CL-CURRENT: 514/12; 514/2, 514/4, 514/866, 530/324

ABSTRACT:

Agonist analogues of amylin and related pharmaceutical compositions, and methods of

treatment of diabetes and other insulin-requiring states, as well as methods of treatment of hypoglycemia, are provided.

45 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

☐ 24. Document ID: US 5641744 A

L4: Entry 24 of 36 File: USPT Jun 24, 1997

US-PAT-NO: 5641744
DOCUMENT-IDENTIFIER: US 5641744 A

TITLE: Treatment of diabetes mellitus

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Woodstock			GB2

US-CL-CURRENT: 514/4; 514/12, 530/303

ABSTRACT:

The present invention relates to methods of preparing a product or a composition containing amylin or amylin with insulin for treating diabetes mellitus.

17 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

☐ 25. Document ID: US 5578444 A

L4: Entry 25 of 36 File: USPT Nov 26, 1996

US-PAT-NO: 5578444
DOCUMENT-IDENTIFIER: US 5578444 A

TITLE: Sequence-directed DNA-binding molecules compositions and methods

DATE-ISSUED: November 26, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

Edwards; Cynthia A.	Menlo Park	CA
Cantor; Charles R.	Boston	MA
Andrews; Beth M.	Maynard	MA
Turin; Lisa M.	Redwood City	CA
Fry; Kirk E.	Palo Alto	CA

US-CL-CURRENT: 435/6; 435/7.23, 536/23.1

ABSTRACT:

The present invention defines a DNA:protein-binding assay useful for screening libraries of synthetic or biological compounds for their ability to bind DNA test sequences. The assay is versatile in that any number of test sequences can be tested by placing the test sequence adjacent to a defined protein binding screening sequence. Binding of molecules to these test sequence changes the binding characteristics of the protein molecule to its cognate binding sequence. When such a molecule binds the test sequence the equilibrium of the DNA:protein complexes is disturbed, generating changes in the concentration of free DNA probe. Numerous exemplary target test sequences (SEQ ID NO:1 to SEQ ID NO:600) are set forth. The assay of the present invention is also useful to characterize the preferred binding sequences of any selected DNA-binding molecule.

15 Claims, 71 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 48

☐ 26. Document ID: US 5424221 A

L4: Entry 26 of 36 File: USPT Jun 13, 1995

US-PAT-NO: 5424221
DOCUMENT-IDENTIFIER: US 5424221 A
**** See image for Certificate of Correction ****

TITLE: Kit for detection of islet amyloid polypeptide (IAPP)

DATE-ISSUED: June 13, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Westermark; Per	Balinge			SE
Johnson; Kenneth H.	Minneapolis	MN		

US-CL-CURRENT: 436/518; 435/7.92, 435/7.94, 435/7.95, 435/975, 436/501, 436/533, 436/548, 530/387.1, 530/387.9, 530/388.24

ABSTRACT:

This invention is directed to kits for the detection of human islet amyloid polypeptide (IAPP) comprising (a) purified preparations of antibodies which react

specifically with insulin or calcitonin gene-related peptides and (b) a preselected amount of human islet amyloid polypeptide which is essentially free of islet amyloid, which polypeptide is one subunit of islet amyloid and which is prepared by depolymerizing human islet amyloid; or a preselected amount of human islet amyloid polypeptide which is essentially free of islet amyloid and has the amino acid sequence: lys-cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val-His-Se r-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly-Ser-Asn-Thr-Tyr.

13 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 27. Document ID: US 5298605 A

L4: Entry 27 of 36 File: USPT Mar 29, 1994

US-PAT-NO: 5298605
DOCUMENT-IDENTIFIER: US 5298605 A
**** See image for Certificate of Correction ****

TITLE: Antibodies to islet amyloid polypeptide (IAPP) and subunits thereof

DATE-ISSUED: March 29, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Westermark; Per	Balinge			SE
Johnson; Kenneth H.	Minnespolis	MN		

US-CL-CURRENT: 530/387.9; 530/324, 530/327, 530/388.2, 530/388.24, 530/389.2, 530/391.1, 530/808, 530/845

ABSTRACT:

This invention is directed to antibodies which react with human islet amyloid polypeptide and which do not significantly react with insulin or calcitonin gene-related peptides. Preparations of antibodies are provided which bind to islet amyloid polypeptide (IAPP) which is substantially free of islet amyloid, and when isolated from humans, has the following amino acid sequence in positions 1-37:

Lys-Cys-Asn-Thr-Ala-Thr-Cys-Ala-Thr-Gln-Arg-Leu-Ala-Asn-Phe-Leu-Val- His-Ser-Ser-Asn-Asn-Phe-Gly-Ala-Ile-Leu-Ser-Ser-Thr-Asn-Val-Gly- Ser-Asn-Thr-Tyr.

11 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

28. Document ID: US 5281581 A

L4: Entry 28 of 36 File: USPT Jan 25, 1994

US-PAT-NO: 5281581
DOCUMENT-IDENTIFIER: US 5281581 A

TITLE: Treatment of insulin resistance

DATE-ISSUED: January 25, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Woodstock			GB2
Greene, Jr.; Howard	Rancho Sante Fe	CA		

US-CL-CURRENT: 514/12; 424/131.1, 424/143.1, 514/13, 514/14, 514/15

ABSTRACT:

Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects by disclosed methods.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

29. Document ID: US 5276059 A

L4: Entry 29 of 36 File: USPT Jan 4, 1994

US-PAT-NO: 5276059
DOCUMENT-IDENTIFIER: US 5276059 A
**** See image for Certificate of Correction ****

TITLE: Inhibition of diseases associated with amyloid formation

DATE-ISSUED: January 4, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Caughey; Byron	Hamilton	MT		

Race; Richard Hamilton MT

US-CL-CURRENT: 514/647

ABSTRACT:

The invention provides a method of treating a mammal having a condition associated with formation of amyloidogenic protein without deposition of amyloid plaques. This treatment includes administering to the mammal a pharmacologically effective amount of Congo Red or a pharmaceutically acceptable salt or derivative thereof to interfere with amyloidogenic protein formation or to destabilize amyloidogenic protein structures already formed in said mammal. The invention also provides a method of treating a mammal having a condition associated with deposition of amyloidogenic protein in plaques, and a method of inhibiting the transformation of PrP-sen to PrP-res in a tissue culture sample containing PrP-sen.

34 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 30. Document ID: US 5266561 A

L4: Entry 30 of 36 File: USPT Nov 30, 1993

US-PAT-NO: 5266561
DOCUMENT-IDENTIFIER: US 5266561 A

TITLE: Treatment of type 2 diabetes mellitus

DATE-ISSUED: November 30, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Woodstock			GB
Greene, Jr.; Howard	Rancho Santa Fe	CA		

US-CL-CURRENT: 514/12; 514/13, 514/14, 514/15, 514/16, 530/307, 530/324, 530/325, 530/326, 530/327, 530/328, 530/329

ABSTRACT:

Compounds and methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP], or biologically active sub-peptides thereof. Inhibitors include substituted peptides or sub-peptides of amylin or CGRP, cross-linked amylin and amylin agonists, synthetic amylin, anti-amylin receptor antibodies and anti-idiotype antibodies, and antibodies directed to amylin and amylin agonist active sites. Other antagonists include organic compounds which can be screened and assayed for anti-amylin effects

by disclosed methods.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

31. Document ID: US 5260275 A

L4: Entry 31 of 36 File: USPT Nov 9, 1993

US-PAT-NO: 5260275
DOCUMENT-IDENTIFIER: US 5260275 A

TITLE: Hypoglycemics

DATE-ISSUED: November 9, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		
Moore; Candace X.	San Diego	CA		

US-CL-CURRENT: 514/12; 514/13, 514/866

ABSTRACT:

Non-insulin dependent, or type 2, diabetes mellitus in a patient is treated by administering to the patient a hypoglycemic agent that enhances plasma concentrations of amylin and a therapeutically effective amount of an amylin antagonist. Hypoglycemic agents which enhance plasma concentrations of amylin can be sulfonylureas such as glibenclamide and tolbutamide. Amylin antagonists can be amylin 8-37 and CGRP 8-37. Administration of the amylin antagonist in conjunction with the hypoglycemic agent also enhances the blood glucose lowering effects of the hypoglycemic agent.

13 Claims, 13 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

32. Document ID: US 5175145 A

L4: Entry 32 of 36 File: USPT Dec 29, 1992

US-PAT-NO: 5175145
DOCUMENT-IDENTIFIER: US 5175145 A

TITLE: Treatment of diabetes mellitus with amylin agonists

DATE-ISSUED: December 29, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Woodstock			GB2

US-CL-CURRENT: 514/4; 514/12

ABSTRACT:

Novel methods for treating diabetes mellitus and hyperglycemia are described which comprise administering to a diabetic or hypoglycemic subject an amount of an amylin agonist effective to induce amylin activity in said subject. Various amylin agonist compounds, and therapeutic methods utilizing such compounds, are also disclosed.

25 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

[ ] 33. Document ID: US 5164295 A

L4: Entry 33 of 36 File: USPT Nov 17, 1992

US-PAT-NO: 5164295
DOCUMENT-IDENTIFIER: US 5164295 A
**** See image for Certificate of Correction ****

TITLE: Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds

DATE-ISSUED: November 17, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Kisilevsky; Robert	Kingston			CA
Szarek; Walter A.	Kingston			CA
Narindrasorasak; Suree	Kingston			CA

US-CL-CURRENT: 435/7.8; 435/7.92, 435/7.93, 435/7.95, 436/501

ABSTRACT:

A method for identifying compounds useful for treating patients with amyloidosis is disclosed. Compounds are screened according to the present invention to determine their ability to modulate the affinity between amyloid protein and proteins of the extracellular matrix.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

34. Document ID: US 5124314 A

L4: Entry 34 of 36 File: USPT Jun 23, 1992

US-PAT-NO: 5124314
DOCUMENT-IDENTIFIER: US 5124314 A

TITLE: Pharmaceutical compositions containing amylin

DATE-ISSUED: June 23, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cooper; Garth J. S.	Solana Beach	CA		

US-CL-CURRENT: 514/4; 514/12, 514/13, 514/14, 514/15, 514/16, 514/17, 514/3

ABSTRACT:

The present invention relates to pharmaceutical compositions for use in treating diabetes Mellitus or hypoglycemia containing Amylin as the effective additive.

9 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw De

35. Document ID: US 5116948 A

L4: Entry 35 of 36 File: USPT May 26, 1992

US-PAT-NO: 5116948
DOCUMENT-IDENTIFIER: US 5116948 A
**** See image for Certificate of Correction ****

TITLE: Preparations of islet amyloid polypeptide (IAPP) and antibodies to IAPP

DATE-ISSUED: May 26, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Westermark; Per	Dalinge			SE
Johnson; Kenneth H.	Minneapolis	MN		

US-CL-CURRENT: 530/324; 530/303, 530/866

ABSTRACT:

Islet Amyloid Polypeptide substantially free of Islet Amyloid which can be isolated from Islet Amyloid of different mammals and when isolated from humans it has the following amino acid sequence in positions 1-37: ##STR1##

1 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. De

☐ 36. Document ID: US 5112945 A

L4: Entry 36 of 36 File: USPT May 12, 1992

US-PAT-NO: 5112945
DOCUMENT-IDENTIFIER: US 5112945 A
**** See image for Certificate of Correction ****

TITLE: Preparation of islet amyloid polypeptides (IAPP) and antibodies to IAPP

DATE-ISSUED: May 12, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Westermark; Per	Dalinge			SE
Johnson; Kenneth H.	Minneapolis	MN		

US-CL-CURRENT: 530/324; 530/303, 530/327, 530/845

ABSTRACT:

Subunits of the full length 37 amino acid residue human Islet Amyloid Polypeptide, and feline Islet Amyloid Polypeptide essentially free of unpolymerized amyloid are provided. Islet Amyloid Polypeptide (IAPP) may be isolated and purified from amyloid fibrils using depolymerizing agent and chromatographic techniques. The sequences of the purified Islet Amyloid Polypeptides have been determined Purified Islet Amyloid Polypeptides are suitable for induction of anti-IAPP antibodies.

4 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWIC | Draw. De

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Term	Documents

@PD	12130052
(3 AND (@PD < "20000504")).PGPB,USPT,USOC.	36
(L3 AND @PD<20000504).PGPB,USPT,USOC.	36

Display Format: - Change Format

Previous Page Next Page Go to Doc#